The services Panaxea offers include:
Health Technology Assessment
The process of bringing your healthcare innovation to the market is lengthy and complicated. Besides the clinical or humanistic value that your product generates, for example by decreasing complication rate, prolonging survival, improving patient flow, the economic value needs to be demonstrated to healthcare payers.
Using Health Technology Assessment, the value of a novel medical intervention is quantified by simultaneous analysis of effects on patient outcomes and total costs of care associated with the innovation in comparison to the standard of care. An objective measure of the medical innovation’s value is generally required for (national) reimbursement applications.
Health Services & Systems Research
Increasing and changing demands concerning the health of populations and limited resources require our health care organisations and systems to rethink their sustainability. To achieve objectives, such as improved healthcare quality, health outcomes, efficiency and staff satisfaction, we support our clients in making evidence-based decisions. With tailor-made research projects, we provide insights into what works, for whom, at what cost, and under what circumstances. Based on your challenge, we can support you by:
- translating your challenge in a problem statement and evaluation design;
- providing you with state-of-the-art insights and identifying where you can make a difference;
- assessing the feasibility and value of your intervention or strategy;
- assessing its implementation fidelity;
- making evidence-based and practical recommendations;
- present the findings to peer-reviewed journals and conferences.
Health Innovation Assessment Consultancy
If you want to objectively show the advantages and competitiveness of your healthcare innovation to potential investors, future users, payers (reimbursement) or even the media, you can greatly benefit from Panaxea’s Health Innovation Assessment Consultation (HIAC).
We help you prepare yourself for (future) discussions with stakeholders about your innovations. During a 1,5 h discussion, we advise you on how to collect, analyse and present data. HIAC takes into account true multi-stakeholder perspectives on value assessment, the realm of marketplace decision making, and the requirements for a robust assessment of your healthcare innovation.
Adding Evidence to Healthcare Innovation
News & Cases
In de nieuwste editie van nieuwsbrief geven wij een update van het Zinnige Zorg onderzoek multidisciplinaire fractuurpreventie, waarbij we de bevindingen van de expert-interviews delen.
Onderzoek ‘Praktijkvoorbeelden, mogelijkheden en randvoorwaarden voor fractuurpreventie in de eerstelijn’
Nieuwe editie van de nieuwsbrief onderdeel van het ZIN onderzoek ‘Praktijkvoorbeelden, mogelijkheden en randvoorwaarden voor multidisciplinaire fractuurpreventie in de eerstelijn’.
Onderzoek ‘Praktijkvoorbeelden, mogelijkheden en randvoorwaarden voor fractuurpreventie in de eerstelijn’
Thermo Fisher Scientific: safely reduce antibiotic exposure
Antibiotics are a limited resource. At the current pace of injudicious use, all antibiotics will soon become ineffective. Panaxea together with Thermo Fisher developed a health-economic model for the use of Procalcitonin (PCT) to determine whether PCT can cost-effectively reduce the use of antibiotics for sepsis. This brochure displays among other […]
Panaxea joins Flanders Innovation & Entrepreneurship
We’re proud to announce that Panaxea is now a certified service provider for the Flemish government under the SME grants from the Flanders Innovation & Enterpreneurship agency ( http://www.kmo-portefeuille.be/). Flanders Innovation & Entrepreneurship (in Dutch: Agentschap Innoveren & Ondernemen) is a government agency, charged with implementing the economic, innovation and enterprise policy in […]
Articulating the value of diagnostics
Diagnostics face difficulties in current market conditions to obtain reimbursement and to enter the market efficiently. This white paper highlights the challenges, but more importantly also highlights the opportunities in articulating the value of diagnostics. It is explained why tailored health economic evidence is paramount to show the value of […]
Generic decision model for diagnostic tests
To give (potential) clients a preliminary insight in the cost-effectiveness of their diagnostic test, we developed an online generic decision model. This model allows users to compare the cost and effects of a diagnostic test versus not testing by using data they collected themselves, for example data they collected during […]
Courses
Building upon our expertise and experience, Panaxea can organize or contribute to courses, seminars and workshops on a wide range of topics in the field of health technology assessment. For this, we can build on years of experience in teaching to students of the University of Twente. In particular, Panaxea […]
Systematic literature review
For a medical device company developing blood glucose meters, we performed a systematic literature review on self-monitoring of blood glucose levels among patients with type 2 diabetes. The report covered an analysis of the burden of the disease and the cost-effectiveness of blood glucose self-monitoring. Cost tables, specifying the cost […]
Market access and reimbursement report
A medical device company has developed a new technology that could improve the visualization and treatment of the affected heart tissue during catheter ablations of the left atrium of the heart. They were interested in getting an overview of the market access and reimbursement regulations in the Netherlands and Belgium […]
Cost-effectiveness and budget impact model for a diagnostic test
Allergic Rhinitis (AR) is a condition where an inflammatory reaction of the immune system is caused by specific allergens. Respiratory AR affects around 15% of the people in the Netherlands. Mostly, AR is treated with symptomatic treatment, but immunotherapy potentially offers a curative treatment by minimizing sensitivity to the allergen. […]
Health Economic Modeling
For a global health company we evaluated the expected incremental cost-effectiveness of one of their products. The cost-effectiveness outcome was needed to support adjuvant therapy decision making versus current clinical practice in the Netherlands. We… developed a Markov model to project distant recurrences survival, quality-adjusted life expectancy and direct medical […]
Time-and-motion study
For a large pharmaceutical company, Panaxea was asked to perform a time-and-motion study to compare two administration methods of medicine.
Impact-analysis public-private partnership (PPP)
In this project we performed an impact-analysis on scientific, translational/clinical and socio-economic aspects of a public-private partnership (PPP)
Health economic analysis of a POCT assay
Point of Care Testing (POCT) is generally perceived to be more expensive on a unit-cost base than testing performed in a centralized laboratory. Consequently, introducing a new treatment protocol in the hospital setting, involving an increase in the number of POCT analyses performed, requires a thorough analysis of accompanying costs […]
Decision analytic support model to guide implementation of laboratory assay
Decision analytic support model could be populated with hospital-specific data, and could thereby guide implementation decisions at local and hospital level
